...
首页> 外文期刊>The Journal of Musculoskeletal and Neuronal Interactions >Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats
【24h】

Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats

机译:阿法骨化醇可预防与年龄有关的骨质流失,并引起老年雄性大鼠的骨形成异常

获取原文
           

摘要

The current study was designed to investigate the skeletal effects of alfacalcidol in aged rats. Eighteen-month-old male rats were treated with 0, 0.1, or 0.2 ìg/kg/d of alfacalcidol by daily oral gavage, 5 days/week for 12 weeks. At the beginning of the treatments, one group of rats was euthanized to serve as a baseline control. At the end of the study, the second lumbar vertebrae and the right tibial diaphysess were processed for bone histomorphometric analysis. The fourth lumbar vertebrae were subjected to strength testing. The control group of rats at 21 months of age had decreased serum testosterone levels and decreased cancellous bone mass associated with increased bone turnover on the trabecular surface. The older rats had increased bone turnover on the endocortical surface and decreased bone formation on the periosteal surface compared with the 18-month group. In contrast, alfacalcidol treatment increased cancellous and cortical bone mass in aged male rats. Trabecular bone resorption was decreased whereas bone formation was maintained or increased in the rats treated with alfacalcidol. In addition, endocortical bone formation was decreased whereas periosteal bone formation was increased in the rats treated with alfacalcidol compared with vehicle-treated rats. Marrow trabecular bone area was increased by alfacalcidol treatment in tibial diaphyses. Furthermore, bone strength of the lumbar vertebral body was increased after alfacalcidol treatment. An atypical pattern of bone formation on endosteal bone surfaces was seen in the rats treated with alfacalcidol. The atypical bone formation is characterized by small, focal packets of newly formed bone on trabecular and endocortical bone surfaces. This gave the appearance of the formation of "bone buds" emanating from trabecular surfaces. These bony outgrowths were mineralized and demonstrated significant fluorochrome label indicating recent mineralization. Also, lamellae of the bony buds did not run parallel to those of the trabecular plate to which they are attached. Arrest lines presented in most of the "bone buds". In summary, alfacalcidol treatment increased cancellous and cortical bone mass and improved bone strength, resulting in the prevention of age-related bone loss in aged male rats. An atypical pattern of bone formation observed in this study may be a result of minimodeling based bone formation stimulated by alfacalcidol treatment.
机译:本研究旨在研究阿法骨化醇对老年大鼠的骨骼作用。对18个月大的雄性大鼠每天口服管饲法,以0、0.1或0.2μg/ kg / d的阿法骨化醇治疗,每天5天/周,持续12周。在治疗开始时,对一组大鼠实施安乐死以作为基线对照。在研究结束时,对第二个腰椎和右胫骨干phy进行了处理,以进行骨组织形态分析。对第四腰椎进行强度测试。在21个月大时,对照组大鼠的血清睾丸激素水平降低,松质骨量减少,与小梁表面的骨转换增加有关。与18个月组相比,老年大鼠的皮质内膜表面的骨转换增加,而骨膜表面的骨形成减少。相反,阿法骨化醇治疗可增加老年雄性大鼠的松质骨和皮质骨量。用阿法骨化醇治疗的大鼠小梁骨吸收减少,而骨形成得以维持或增加。另外,与赋形剂处理的大鼠相比,用阿法骨化醇治疗的大鼠的皮质内骨形成减少,而骨膜的骨形成增加。阿法骨化醇治疗胫骨干phy端的骨髓小梁骨面积增加。此外,阿法骨化醇治疗后腰椎骨强度增加。在用阿法骨化醇治疗的大鼠中观察到了骨内膜骨表面上的骨形成的非典型模式。非典型骨形成的特征在于小梁和皮质内骨表面上新形成的骨的小,局灶性小包。这给出了从小梁表面发出的“骨芽”形成的外观。这些骨质产物被矿化,并显示出明显的荧光色素标记,表明近期有矿化。而且,骨芽的薄片不平行于它们附着的小梁板的薄片。大多数“骨芽”中都出现了逮捕线。总之,阿法骨化醇治疗增加了松质骨和皮质骨的质量,并改善了骨强度,从而预防了老年雄性大鼠中与年龄有关的骨质流失。在这项研究中观察到的骨形成的非典型模式可能是由阿法骨化醇治疗刺激的基于小模型的骨形成的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号